The 2^nd Annual BioCapital Europe Expands To Include non-Benelux Companies

BioCapital Europe, the Biotechnology Investor Conference organised by Fortis Bank and Life Sciences Partners, to take place at the Barbizon Palace Hotel, Amsterdam on 6 April 2004

 

 

Amsterdam , The Netherlands , 17 Dec 2003 :  BioCapital Europe 2004, the biotech investor conference which in its inaugural year showcased biotechnology companies predominantly from Belgium and The Netherlands, will next year expand to include more companies from surrounding regions.  Companies will present to an invited audience of venture capitalists, institutions, and biotech and pharmaceutical companies.  There will be keynote speakers from the pharmaceutical, biotechnology and financial industries.

 

BioCapital Europe 2004 will be held on 6 April 2004 at the Barbizon Palace Hotel, Amsterdam , and will again be organised by Fortis Bank and Life Sciences Partners.

BioCapital Europe is a one-day conference offering a unique opportunity to view the pick of Benelux-based Biotechnology companies complemented with leading Life Sciences firms from Germany , France and the UK . Attendees - by personal invitation only – will include venture capitalists and biotech/pharmaceutical executives, all looking to find the best investment opportunities within the biotechnology market.  Registration costs €995 per delegate and can be done online at: www.biocapitaleurope.com

-ends-

Fortis Bank is a member of the Fortis Group, an international financial services provider active in the fields of insurance, banking and investments. With a market capitalisation of EUR 20 billion and around 68,000 employees, Fortis ranks in the top 20 European financial institutions. Fortis Bank offers a full range of investment banking services, including private placements, public equity offerings and mergers & acquisitions. Within biotechnology, Fortis Bank has created a research-driven, global approach to its investment banking and brokerage activities. Our dedicated biotech team operates from Amsterdam , New York and Boston . 
www.investmentbanking.fortisbank.com  

Life Sciences Partners was one of the first European private equity funds with a dedicated human life science focus. LSP was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Previously, Martijn Kleijwegt and Frits van der Have were responsible for developing the life science portfolio at Euroventures Benelux since 1988. Tom Schwarz co-founded U-Gene Research, a biotech/clinical research company, which he successfully sold to a major research organization. Presently LSP has invested in over twenty early and later stage biotech companies in the Benelux , Germany , France , UK and the USA .  LSP has offices in Amsterdam and Munich .  www.lsp.nl

For further enquiries:

Conference organiser:

Anita Howard, BioCapital Europe

Tel: + 44 20 8767 5678

Email: anita@biocapitaleurope.com

Press enquiries:

Fiona Brown MIPR, Northbank Communications

Tel: +44 20 7886 8155

Email: f.brown@northbankcommunications.com